Sagaliam Acquisition Corp. Acquires Biogenysis and Virogentics
Enzolytics, Inc. announced on September 18 that it sold two of its wholly owned subsidiaries, Biogenysis, Inc. and Virogentics, Inc., to Sagaliam Acquisition Corp. in a transaction valued at $450 million. Enzolytics is a Texas-based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. Biogenysis uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus... Read More »
SANUWAVE Health Merges with SPAC SEP Acquisition Corp.
SANUWAVE Health Inc. has entered into a definitive merger agreement with SEP Acquisition Corp. Upon completion of the proposed transaction, the combined company is expected to operate under the SANUWAVE name and trade on the NASDAQ Capital Market under the symbol “SNWV”. SANUWAVE Health is commercial stage medical device company. It has two FDA approved products and its lead product, UltraMIST®, has nationwide schedule 1 reimbursement from CMS. According to its FY 2022 financial report, SANUWAVE had FY 2022 revenues of $16.7 million. SEP Acquisition Corp. is a Houston-based special purpose acquisition company (SPAC) affiliated with Sweat Equity Partners and Mercury Life... Read More »
Spectral MD Holdings to be Listed on Nasdaq Through Business Combination with Rosecliff Acquisition Corp I SPAC
Spectral MD Holdings, Ltd. announced on April 11 that it has entered into an agreement to combine with Rosecliff Acquisition Corp I, a special purpose acquisition company (SPAC) listed on Nasdaq. The combined company expects to operate under the name Spectral AI and to be listed on Nasdaq under the symbol “MDAI”. The combined company will operate under the same management team, led by Spectral MD founder and CEO Wensheng Fan with current Spectral MD shareholders rolling 100% of their equity into the transaction. Net proceeds of the proposed transaction will be used to accelerate readiness for material potential federal contracts, to enhance Spectral MD’s efforts for broad... Read More »
DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.
HH&L Acquisition Co., a publicly traded special purpose acquisition company (SPAC) targeting the healthcare sector in Asia, and DiaCarta, Ltd., a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, announced on October 14 that they have entered into a definitive business combination agreement. The transaction implies a pre-money equity value of $460 million for DiaCarta on a fully diluted basis. The transaction is expected to close in the first quarter of 2021 and will position DiaCarta to capitalize on significant future growth within existing and new markets. Upon closing of the transaction, the combined company will be listed on the... Read More »